1229383-70-3

Basic information

• Product Name: isoxazolo[5,4-b]pyridin-3-yl-carbamic acid phenyl ester
• CAS NO: 1229383-70-3
• Molecular Weight: 255.233
• Mol File: 1229383-70-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: isoxazolo[5,4-b]pyridin-3-yl-carbamic acid phenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: isoxazolo[5,4-b]pyridin-3-yl-carbamic acid phenyl ester(1229383-70-3)
• EPA Substance Registry System: isoxazolo[5,4-b]pyridin-3-yl-carbamic acid phenyl ester(1229383-70-3)

Safety Data

• Hazardous Substances Data: 1229383-70-3(Hazardous Substances Data)

Upstream product

• 92914-74-4 3-aminoisoxazolo[5,4-b]pyridine 
• 1885-14-9 phenyl chloroformate 

Downstream Products

• 1230019-07-4 4-[3-(4-chloro-phenoxy)-benzyl]-piperazine-1-carboxylic acid isoxazolo[5,4-b]pyridin-3-ylamide 

Relevant articles and documents

Heteroaryl urea inhibitors of fatty acid amide hydrolase: Structure-mutagenicity relationships for arylamine metabolites

The structure-activity relationships for a series of heteroaryl urea inhibitors of fatty acid amide hydrolase (FAAH) are described. Members of this class of inhibitors have been shown to inactivate FAAH by covalent modification of an active site serine with subsequent release of an aromatic amine from the urea electrophile. Systematic Ames II testing guided the optimization of urea substituents by defining the structure-mutagenicity relationships for the released aromatic amine metabolites. Potent FAAH inhibitors were identified having heteroaryl amine leaving groups that were non-mutagenic in the Ames II assay.

HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE

Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).